Joyce Sutcliffe, Senior Vice President of Biology at Tetraphase, to give featured presentation at 7th Anti-Infectives Partnering & Deal-Making (Oct 7-8, 2010 in Boston, MA)

Joyce Sutcliffe, Senior Vice President of Biology at Tetraphase, will give a featured presentation on “TP-434: A Novel, Gram-Negative Antibiotic in Clinical Development” at the 7th Anti-Infectives Partnering and Deal-making Summit to be held in Boston, MA on October 7-8, 2010 by GTCbio. Infections caused by multidrug-resistant (MDR) gram-negative bacterial pathogens cause great morbidity and mortality worldwide, with a recent study concluding that the spread of resistant pathogens has resulted in higher healthcare and societal costs of $13.5 billion dollars annually in the US. TP-434, a novel fluorocycline, was discovered using a break-through chemistry platform that forms the basis of Tetraphase’s proprietary product engine. TP-434 shows potent activity against a broad range of MDR aerobic and anaerobic gram-negative and gram-positive pathogens both in vitro and in vivo in a variety of murine infection models challenged with MRSA, Streptococcus pneumoniae, S. pyogenes or MDR gram-negative bacteria. With its excellent plasma exposure, volume of distribution, and 40-hour half-life, TP-434 has great potential as a once-daily treatment for serious bacterial infections, especially those caused by MDR gram-negative pathogens